Elicera completes Phase I segment of CARMA study
Elicera Therapeutics completed the Phase I part of its CARMA study of ELC-301, with a complete metabolic response in 8 of 12 patients, or 67%.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Reuters reports that Elicera Therapeutics AB has completed the Phase I part of its CARMA study evaluating ELC-301.
The company said a complete metabolic response was recorded in 8 of the 12 patients. That represents 67% of participants in the Phase I study.
why it matters
Completion of Phase I and the reported response rate mark important milestones in the program’s development and may shape market attention toward the biotechnology company.
sources
- Elicera Therapeutics Completes Phase I Part Of Carma Study — Reuters, 12 October 2026 at 11:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗